Study Design: This was a prospective cohort study of 165 subjects with a primary diagnosis of major depressive disorder.* The study compared 8 weeks of treatment guided by GeneSight to unguided treatment as usual (TAU).
Significant improvement in depression scores: Greater reduction in depression ratings was observed across the duration of the study for the GeneSight guided group, showing 70% greater improvement in depressive symptoms compared to TAU at 8 weeks.
Higher response rates: When clinicians used the GeneSight report to guide treatment, patients were 2.1 times more likely to respond to their medications compared to treatment without GeneSight.
Higher physician and patient satisfaction: Almost three times as many physicians in the GeneSight guided group perceived their patients to be very highly satisfied with their care compared to the unguided group. Physician reporting of confidence in choice of medication and treatment and satisfaction with care was also substantially higher in the GeneSight guided group.
*Minimum Score of 14 on the 17-item Hamilton Rating Scale for Depression (HAM-D17). QIDS-C16 (Quick Inventory of Depressive Symptomatology-Clinician Rated) PHQ-9=Patient Health Questionnaire